タイトル | Systematic Potency and Property Assessment of VHL Ligands and Implications on PROTAC Design. |
---|
ジャーナル・号・ページ | Chemmedchem, Vol. 18, Page e202200615-e202200615, Year 2023 |
---|
掲載日 | 2022年10月19日 (構造データの登録日) |
---|
著者 | Krieger, J. / Sorrell, F.J. / Wegener, A.A. / Leuthner, B. / Machrouhi-Porcher, F. / Hecht, M. / Leibrock, E.M. / Muller, J.E. / Eisert, J. / Hartung, I.V. / Schlesiger, S. |
---|
リンク | Chemmedchem / PubMed:36749883 |
---|
手法 | X線回折 |
---|
解像度 | 1.72 - 3.18 Å |
---|
構造データ | PDB-8bdi: VCB in complex with compound 32 手法: X-RAY DIFFRACTION / 解像度: 2.108 Å PDB-8bdj: VCB in complex with compound 30 手法: X-RAY DIFFRACTION / 解像度: 2.02 Å PDB-8bdl: VCB in complex with compound 27 手法: X-RAY DIFFRACTION / 解像度: 2.295 Å PDB-8bdm: VCB in complex with compound 26 手法: X-RAY DIFFRACTION / 解像度: 2.021 Å PDB-8bdn: VCB in complex with compound 23 手法: X-RAY DIFFRACTION / 解像度: 2.76 Å PDB-8bdo: VCB in complex with compound 21 手法: X-RAY DIFFRACTION / 解像度: 2.8 Å PDB-8bds: Ternary complex between VCB, BRD4-BD1 and PROTAC 48 手法: X-RAY DIFFRACTION / 解像度: 1.72 Å PDB-8bdt: Ternary complex between VCB, BRD4-BD2 and PROTAC 51 手法: X-RAY DIFFRACTION / 解像度: 2.7 Å PDB-8bdx: Ternary complex between VCB, BRD4-BD2 and PROTAC 48 手法: X-RAY DIFFRACTION / 解像度: 2.93 Å PDB-8beb: Ternary complex between VCB, BRD4-BD1 and PROTAC 49 手法: X-RAY DIFFRACTION / 解像度: 3.18 Å |
---|
化合物 | ChemComp-QF7: (2~{S},4~{R})-1-[(2~{S})-2-[(1-fluoranylcyclopropyl)carbonylamino]-3,3-dimethyl-butanoyl]-~{N}-[(1~{S})-3-(methylamino)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]-3-oxidanylidene-propyl]-4-oxidanyl-pyrrolidine-2-carboxamide
ChemComp-QE0: (2~{S},4~{R})-~{N}-[(1~{S})-1-[4-chloranyl-2-(2-methoxyethoxy)phenyl]ethyl]-1-[(2~{R})-3-methyl-2-(3-methyl-1,2-oxazol-5-yl)butanoyl]-4-oxidanyl-pyrrolidine-2-carboxamide
ChemComp-QF3: (2~{S},4~{R})-~{N}-[(1~{S})-1-[2-(2-methoxyethoxy)-4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]-1-[(2~{R})-3-methyl-2-(3-methyl-1,2-oxazol-5-yl)butanoyl]-4-oxidanyl-pyrrolidine-2-carboxamide
ChemComp-QE9: (2~{S},4~{R})-~{N}-[[2-(2-methoxyethoxy)-4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]-1-[(2~{R})-3-methyl-2-(3-methyl-1,2-oxazol-5-yl)butanoyl]-4-oxidanyl-pyrrolidine-2-carboxamide
ChemComp-QFR: (2~{R})-3-methyl-1-[(2~{S},4~{R})-2-[(5~{R})-5-methyl-5-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]-4~{H}-1,2,4-oxadiazol-3-yl]-4-oxidanyl-pyrrolidin-1-yl]-2-(3-methyl-1,2-oxazol-5-yl)butan-1-one
ChemComp-QFF: (2~{S},4~{R})-1-[(2~{R})-3-methyl-2-(3-methyl-1,2-oxazol-5-yl)butanoyl]-~{N}-[4-(4-methyl-1,3-thiazol-5-yl)phenoxy]-4-oxidanyl-pyrrolidine-2-carboxamide
ChemComp-QIY: (2S,4R)-N-[(1S)-1-(4-chlorophenyl)-3-[2-[2-[2-[2-[2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8$l^{5},11,12-tetrazatricyclo[8.3.0.0^{2,6}]trideca-2(6),4,7,10,12-pentaen-9-yl]ethanoylamino]ethoxy]ethoxy]ethoxy]ethylamino]-3-oxidanylidene-propyl]-1-[(2R)-3-methyl-2-(3-methyl-1,2-oxazol-5-yl)butanoyl]-4-oxidanyl-pyrrolidine-2-carboxamide
ChemComp-QLX: (2~{S},4~{R})-~{N}-[(1~{S})-3-[2-[2-[2-[2-[2-[(9~{S})-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.0^{2,6}]trideca-2(6),4,7,10,12-pentaen-9-yl]ethanoylamino]ethoxy]ethoxy]ethoxy]ethylamino]-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]-3-oxidanylidene-propyl]-1-[(2~{R})-3-methyl-2-(3-methyl-1,2-oxazol-5-yl)butanoyl]-4-oxidanyl-pyrrolidine-2-carboxamide
ChemComp-QIK: (2~{S},4~{R})-~{N}-[(1~{S})-3-[4-[2-[(9~{S})-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.0^{2,6}]trideca-2(6),4,7,10,12-pentaen-9-yl]ethanoylamino]butylamino]-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]-3-oxidanylidene-propyl]-1-[(2~{R})-3-methyl-2-(3-methyl-1,2-oxazol-5-yl)butanoyl]-4-oxidanyl-pyrrolidine-2-carboxamide
|
---|
由来 | - homo sapiens (ヒト)
|
---|
キーワード | LIGASE / PROTAC / degrader / complex / E3 ligase / VHL / VCB / VH032 / Ternary complex |
---|